Navigation Links
Encorium Group Signs Approximately $2.0 Million of New Business Contracts
Date:4/27/2009

WAYNE, Pa., April 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced the signing of approximately $2.0 million of new business contracts, consisting of both new business contracts and repeat business to be conducted primarily in Europe. Revenue recognition will begin in the second quarter of 2009 on a proportional basis as services are performed on each project. The backlog of the company was approximately $31.0 million at April 15, 2009.

Dr. David Ginsberg, Encorium Group's Chief Executive Officer, stated, "The contracts represent a continuation of our success in the field of vaccines and oncology and we plan to continue to further develop our already significant expertise in the therapeutic arenas of vaccines (both preventive and therapeutic) as well as oncology."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermato
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
2. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
3. Encorium Reports Third Quarter 2008 Financial Results
4. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
5. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
6. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Disabled and other vulnerable groups more susceptible to terrorism fears
9. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
10. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... 3SBio Inc. (Nasdaq:,SSRX), a leading China-based biotechnology company ... today,announced the results of the shareholder votes at ... September 12, 2008 (Friday) at 10:00 a.m.,(Beijing time)., ... Dr. Jing Lou,Liping Xu, Bin Huang, Lawrence S. ...
... in Routine Vaccination Program ... -, COLLEGEVILLE, Pa., Sept. 15 Wyeth,Pharmaceuticals, ... today announced that,South Africa has initiated an immunization ... Vaccine,Adsorbed), a vaccine which helps protect infants and ...
... Bulletin Board: CBPC) announced today that it has filed ... an amendment to its Certificate,of Incorporation to effect a ... ("Common Stock") will begin trading on a,reverse-split basis on ... By unanimous written consent dated July 3, 2008 the ...
Cached Biology Technology:South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 2South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 3South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 4China Biopharma Effects 1 for 100 Reverse Stock Split 2China Biopharma Effects 1 for 100 Reverse Stock Split 3
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst ... time half of the world,s population will have a ... Europe . Asia ... the market accounting for more than 60% of all ... Acuity,s report  -- "The Global National eID ...
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2
... wetlands are vital to the water cycle and ... GlobWetland, an ESA-led initiative in collaboration with the ... by using satellite imagery to provide detailed wide-area ... local conservation efforts. , Because the success of ...
... bacterial surface proteins that generate the strongest immune ... Chicago have created a vaccine that significantly protects ... Staphylococcus aureus, the most common cause of hospital-acquired ... illness. , The vaccine protected mice against ...
... an experimental targeted therapy with a common anti-inflammatory ... cancer, researchers at UCLA's Jonsson Cancer Center reported. ... anti-inflammatory drug Celebrex increased response rates in lung ... Reckamp, an assistant professor of hematology/oncology and lead ...
Cached Biology News:African wetland managers armed with new technology 2MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Combination therapy shows promising results in patients with advanced lung cancer 2Combination therapy shows promising results in patients with advanced lung cancer 3
...
... is the first fully genetically encoded fluorescent ... intracellular hydrogen peroxide (H2O2), one of the ... the basis of yellow fluorescent protein inserted ... protein OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity ...
Alexa Fluor 647 anti-mouse Qa-2...
... essential for hunting and analyzing the ... as EST sequencing projects, microarrays, functional ... is developed for normalization of cDNA ... for directional cloning. While most normalization ...
Biology Products: